AdverseEvent.ai
This page presents data from the FDA Adverse Event Reporting System (FAERS) and the FDA-approved drug label. A report submitted to FAERS does not prove a drug caused the reported event. Always consult a healthcare provider about medications.

Oxaliplatin

platinum-based drug
Last updated: October 14, 2026
Preview tracking

Oxaliplatin is a medication, a platinum-based drug. According to the FDA-approved label, Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. FAERS contains 73,751 submissions naming this drug from 2004 through 2026; the top three reactions cited are diarrhoea, nausea, and off label use.

Most-Reported Reactions

Counts of the reactions most often cited in FAERS submissions that named Oxaliplatin. Inclusion here does not establish causation - submitters describe what was observed, not what was confirmed. One submission can list several reactions, so the totals exceed the report count.

DIARRHOEA 6,870 (9.3%) NAUSEA 5,479 (7.4%) OFF LABEL USE 4,668 (6.3%) VOMITING 4,415 (6.0%) NEUROPATHY PERIPHERAL 4,317 (5.9%) DISEASE PROGRESSION 4,314 (5.8%) NEUTROPENIA 4,207 (5.7%) THROMBOCYTOPENIA 3,526 (4.8%) DYSPNOEA 3,084 (4.2%) PYREXIA 2,869 (3.9%) FATIGUE 2,822 (3.8%) ANAEMIA 2,426 (3.3%) ASTHENIA 2,360 (3.2%) DEATH 2,314 (3.1%) DRUG INEFFECTIVE 2,147 (2.9%)

Patient Demographics

Patient sex and age across the FAERS submissions that named Oxaliplatin. Percentages here are computed only from submissions where these fields were filled in - many leave them blank.

By Sex

Female Male Unknown

By Age Group

0-17 18-44 45-64 65+

Severity Outcomes

Severity flags recorded across the 73,751 FAERS submissions that named Oxaliplatin. Each bar shows the count of those reports carrying that flag. A single case can carry more than one (a hospitalization that became life-threatening, for example), so these bars are independent rates - they don't sum to 100%. Inclusion of a case under any flag does not establish that the drug caused the outcome.

DEATH 10,724 (14.5%) HOSPITALIZATION 29,031 (39.4%) LIFE-THREATENING 6,508 (8.8%) DISABLING 1,091 (1.5%)

Submissions Per Quarter

Quarterly count of FAERS submissions that named Oxaliplatin. Ups and downs on this chart can track prescribing volume, news cycles, or shifts in how reports get filed, rather than the drug becoming safer or more dangerous.

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

From the FDA-Approved Label

Excerpts from the official FDA-approved prescribing information for Oxaliplatin. This is the authoritative source on indications, warnings, and known adverse reactions.

Indications

1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )

Adverse Reactions (from label)

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Peripheral Sensory Neuropathy [see Warnings and Precautions ( 5.2 )] Severe Myelosuppression [see Warnings and Precautions ( 5.3 )] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions ( 5.4 )] Pulmonary Toxicity [see Warnings and Precautions ( 5.5 )] Hepatotoxicity [see Warnings and Precautions ( 5.6 )] QT Interval Prolongation and Ventricular Arrhythmias [see Warnings and Precautions ( 5.7 )] Rhabdomyolysis [see Warnings and Precautions ( 5.8 )] Hemorrhage [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence greater than or equal to 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6. (continues in label)

FDA label effective date: 2024-10-03

Disclaimer

AdverseEvent.ai is not affiliated with the FDA. Adverse-event counts come from the FDA Adverse Event Reporting System (FAERS). Drug labels come from the FDA drug label dataset. A report submitted to FAERS does not prove a drug caused the reported event — always consult a healthcare provider about medications. This site is for informational purposes only and is not medical advice.